In an effort to develop novel therapeutic approaches against AML, gilteritinib, a dual FLT3, and AXL (from anexelekto, “uncontrolled”) inhibitor, was approved as a second generation FLT3 inhibitor by the Food and Drug Administration (FDA) of the USA in November 2018. The gene discussed is FLT3; the disease is acute myeloid leukemia.